Immune system study in lung cancer patients starting immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study is looking at how the immune system responds to immunotherapy in people with advanced non-small cell lung cancer. By collecting sputum (mucus from your lungs) and blood samples, researchers hope to find clues that could help predict treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Diagnosed with non-small cell lung cancer that is locally advanced or has spread (metastatic)
- About to start a PD-1 or PD-L1 immunotherapy drug (like nivolumab or pembrolizumab), with or without chemo
- Never had this kind of immunotherapy before
- Covered by social security or national health insurance
- Willing to give written permission to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
This study is looking at immune markers in people with advanced non-small cell lung cancer (NSCLC) that cannot be cured. It tests how well the immune system responds to treatment, and may help guide future care.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.